| Biomarker ID | 1220 |
| PMID | 24097862 |
| Year | 2013 |
| Biomarker | Semaphorin 4F (SF4) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (high levels) had increased risk of biochemical recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 5.43; (95% CI: 2.19–13.40) |
| Effect on Pathways | NA |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 240 patients were chosen for the study out of which 28 had biochemical recurrence |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p = 0.0002 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | high expression group (S4F ≥ 4.35; 13 cases) or low expression group (S4F < 4.35; 227 cases) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SF4 |